Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

(NVLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 36,801
  • Shares Outstanding, K 15,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,460 K
  • 36-Month Beta 0.01
  • Price/Sales 2.36
  • Price/Cash Flow N/A
  • Price/Book 0.76
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.09
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/07/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Announces the Completion of an Immuno-Oncology Merger with Nivalis Therapeutics

Research Desk Line-up: Biogen Post Earnings Coverage

ALPN : 9.68 (-1.22%)
NVLS : 2.40 (+2.13%)
KITE : 179.38 (-0.20%)
BIIB : 315.03 (-1.24%)
Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

EXAS : 45.00 (+3.69%)
IMGN : 6.50 (-0.46%)
NVLS : 2.40 (+2.13%)
RHHBY : 32.0400 (+0.28%)
Nivalis Therapeutics, Inc. Sets Date for Special Meeting of Stockholders

Nivalis Therapeutics, Inc. (NASDAQ: NVLS) announced today that it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Alpine Immune...

NVLS : 2.40 (+2.13%)
KITE : 179.38 (-0.20%)
Shire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View

Shire plc (SHPG) reported first-quarter 2017 earnings of $3.63 per American Depositary Share (ADS), beating the Zacks Consensus Estimate of $3.22 and up 13.8% from the year-ago quarter figure of $3.19....

SHPG : 155.36 (+1.28%)
INFI : 1.16 (unch)
NVLS : 2.40 (+2.13%)
CORI : 10.83 (+1.31%)
AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y

AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter

PGNX : 6.96 (+0.14%)
PTN : 0.60 (unch)
NVLS : 2.40 (+2.13%)
AMAG : 18.45 (-1.86%)
What's in Store for Nivalis (NVLS) this Earnings Season?

Nivalis Therapeutics, Inc. (NVLS) is expected to report first-quarter 2017 results early next month. Last quarter, the company had a positive surprise of 9.09%.

RARE : 52.52 (-0.21%)
PTI : 1.99 (+5.85%)
VRTX : 152.06 (-0.43%)
NVLS : 2.40 (+2.13%)
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

CORT : 17.51 (-2.07%)
GRFS : 20.76 (-0.14%)
INFI : 1.16 (unch)
NVLS : 2.40 (+2.13%)
Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to Combine

--- Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development -

NVLS : 2.40 (+2.13%)
KITE : 179.38 (-0.20%)
How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

On Monday, March 06, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Monday's trading session in bearish territories....

ADXS : 4.73 (-4.06%)
CRBP : 6.55 (unch)
NVLS : 2.40 (+2.13%)
VNDA : 18.85 (+2.45%)
Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat Added to Ivacaftor for Treatment of Cystic Fibrosis

Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with cystic fibrosis (CF), today announced topline results from the...

NVLS : 2.40 (+2.13%)

Business Summary

Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.

See More

Support & Resistance

2nd Resistance Point N/A
1st Resistance Point N/A
Last Price 2.40
1st Support Level N/A
2nd Support Level N/A

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.